| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HEP.30528 |
| P698 | PubMed publication ID | 30693544 |
| P50 | author | Li-Fan Lu | Q40637052 |
| Chuanhui Peng | Q88380791 | ||
| Bing Xin | Q91262177 | ||
| P2093 | author name string | Liang Wen | |
| Gen-Sheng Feng | |||
| Jin Lee | |||
| Chia-Hao Lin | |||
| Gaowei Wang | |||
| Panyisha Wu | |||
| P2860 | cites work | Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions | Q26865859 |
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Immune checkpoint blockade: a common denominator approach to cancer therapy | Q28083981 | ||
| Interferons, immunity and cancer immunoediting | Q28270336 | ||
| Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer | Q30746254 | ||
| Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells | Q33590390 | ||
| Induction of B7-H1 and B7-DC expression on airway epithelial cells by the Toll-like receptor 3 agonist double-stranded RNA and human rhinovirus infection: In vivo and in vitro studies | Q33605239 | ||
| FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis | Q34791002 | ||
| RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity | Q34910463 | ||
| CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells | Q35971414 | ||
| Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. | Q36106006 | ||
| Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients | Q36821248 | ||
| Liver: An organ with predominant innate immunity | Q37048206 | ||
| Twelve immunotherapy drugs that could cure cancers | Q37118201 | ||
| Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors | Q37641401 | ||
| Immune surveillance by the liver | Q38139201 | ||
| Hydrodynamic transfection for generation of novel mouse models for liver cancer research | Q38183539 | ||
| Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design | Q38192888 | ||
| Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. | Q38256660 | ||
| The yin and yang of evasion and immune activation in HCC. | Q38367030 | ||
| Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. | Q38534459 | ||
| Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. | Q38776860 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| Emerging Opportunities and Challenges in Cancer Immunotherapy. | Q38809772 | ||
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 | ||
| Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance | Q44002901 | ||
| Toll-like receptor 3 promotes cross-priming to virus-infected cells. | Q45511446 | ||
| A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells | Q46184041 | ||
| Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions. | Q46232926 | ||
| β-Catenin Deficiency in Hepatocytes Aggravates Hepatocarcinogenesis Driven by Oncogenic β-Catenin and MET. | Q46735091 | ||
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Q50046367 | ||
| Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice. | Q50953925 | ||
| Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET. | Q52367078 | ||
| Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma | Q56373211 | ||
| Hepatocellular carcinoma | Q57756376 | ||
| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial | Q89012806 | ||
| P433 | issue | 6 | |
| P921 | main subject | liver cancer | Q623031 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 2518-2532 | |
| P577 | publication date | 2019-03-13 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice | |
| P478 | volume | 69 |
| Q93055681 | Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer |
| Q97888250 | Improving the Efficacy of Liver Cancer Immunotherapy: the Power of Combined Preclinical and Clinical Studies |
| Q90270048 | Inflammatory Mechanisms of HCC Development |
| Q97528913 | Long Noncoding RNA LINC01134 Promotes Hepatocellular Carcinoma Metastasis via Activating AKT1S1 and NF-κB Signaling |
| Q64943764 | Tumor immunology and immunotherapy: a journey I started from Hangzhou. |
Search more.